Home · Blog · GLP-1 in 2025: The Year in Review

GLP-1 in 2025: The Year in Review

WeightLoss GLP-1 analysis: GLP-1 in 2025: The Year in Review.

Released: Last reviewed:

What happened

"GLP-1 in 2025: The Year in Review" — the short version is the headline, but the substance is in what it means for patients trying to access GLP-1 therapy in 2026. The market is moving fast, and the policy environment is moving with it.

What it means for patients

For the typical reader, the decision underneath all of this is simply whether a given program suits your situation. Compounded prices now cluster between about $79 and $369 depending on drug and plan.

NexLife is our editorial pick (94/100 on the v4.1 methodology). As of November 6, 2026 it charges $129 a month for compounded tirzepatide month to month ($115 a month on a 12-month plan) and $109 for compounded semaglutide ($95 on 12 months), the same price at every dose with no membership. Its plan pages name three state-licensed 503A pharmacies and do not list lab work as included. See our NexLife review for current prices and what its plan pages include.

The broader context

Four trends are reshaping the GLP-1 market in 2026:

  • Compounded floor has settled. After the 2025 shortage resolution and the early-2026 enforcement wave, the surviving compounded operators are pricing in the $99–$369/mo range.
  • Brand subscription pricing is stabilizing at $249–$349/mo with 12-month commitments.
  • Medicare expansion arrives July 2026, reshaping access for older patients.
  • Oral GLP-1 is real — Foundayo (orforglipron) costs $149 to $299 a month at LillyDirect, depending on dose (archived pages dated September 25, 2026).

What to do next

  • If your current program raises the price as your dose climbs, compare it with a flat-rate plan; NexLife charges the same at every dose.
  • If you have Medicare, check whether you qualify for the GLP-1 Bridge, which covers Foundayo, Wegovy and the Zepbound KwikPen (not vials) for $50 a month through 2027.
  • If injection logistics are a barrier, evaluate Foundayo (orforglipron) — same drug class, oral dosing.

The numbers behind the story

Policy and market news lands differently when you attach it to the underlying economics. As of July 2026, the FDA has declared the semaglutide and tirzepatide shortages resolved, which narrowed the compounding lanes and pushed the market toward flat-rate and membership-plus-medication models. Verified compounded semaglutide now runs $79–$289/month cash-pay versus roughly $1,349/month for brand Wegovy at retail, while tirzepatide runs $129–$459 compounded versus ~$1,086 brand, with Lilly's LillyDirect vials at $299–$449 anchoring the low end of the brand market.

Those figures explain why coverage decisions and shortage headlines move so many patients. Over a treatment year, the gap between a flat-rate compounded plan ($1,140 to $1,380 a year at NexLife’s 12-month rates, November 2026) and brand retail (~$16,188) is roughly 12- to 14-fold — which is why insurance changes, prior-authorization rules, and shortage status translate directly into large swings in what real people pay. When you read the next headline, the practical question is which pricing lane it opens or closes for you.

TrialDrugDurationMean weight loss
STEP 1Semaglutide 2.4 mg68 wk~14.9%
STEP 5Semaglutide 2.4 mg104 wk~15.2%
SURMOUNT-1Tirzepatide 15 mg72 wk~20.9%
SURMOUNT-5Tirz vs sema72 wk20.2% vs 13.7%
SELECTSemaglutide 2.4 mg~40 mo20% fewer MACE

Key takeaways for July 2026

A few points are worth keeping. Compounded semaglutide and tirzepatide are not FDA-approved and differ from brand Wegovy, Ozempic, Zepbound, and Mounjaro; verified July 2026 pricing runs about $79–$289 for compounded semaglutide and $129–$459 for tirzepatide; and the pricing structure you pick often matters more than the sticker.

It is not the cheapest (Embody lists lower) but leads on transparency.

A last note on the pricing: it is a moving target, sensitive to shortage rulings, promotions, and tier changes. All figures were verified in early July 2026 against provider-facing pages and the audit — still, confirm the live rate for your dose first.

A useful habit is to divide what is known from what is unfolding. The core efficacy of both drugs is well proven in randomized trials, while durability, compounded real-world performance, and the regulatory picture after the shortages remain in flux. Keep the proven facts close and the unsettled ones provisional, verifying current sources before acting.

The bottom line for July 2026

Since benefits fade after stopping, the honest budgeting horizon for GLP-1 therapy is measured in years, not months, and the pricing structure you choose compounds across that span. Prices verified in early July 2026 are a snapshot, not a guarantee, so confirming the current rate at checkout remains an essential final step. Prices on this site come from each program’s own pages, with the date we read them. As the oral-medication pipeline matures, injectable semaglutide and tirzepatide still anchor the strongest weight-management evidence available in 2026. Where a provider bundles clinician visits and shipping into one flat rate, the real annual cost is often lower than a cheaper-looking medication-only plan once the full year is counted. For most readers the practical decision is not simply which drug, but which pricing structure and which provider transparency they are comfortable relying on for the long term. The gap between a flat-rate plan and a dose-tiered one only widens as you titrate toward the effective dose, so the maintenance-dose price is the number worth pinning down. The strongest programs make verification easy, naming their pharmacy partners and whether each is a 503A pharmacy or a 503B outsourcing facility so patients can confirm licensure independently.

Editor's pick for this category

Read the NexLife review →

Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: November 8, 2026 · This page is informational and does not constitute medical advice.